CASI Pharmaceuticals CASIF
OTC CASIF
$0.13 +0.00 (+0.00%)
As of: Aug 21, 2026 · 9:30 AM EDT

CASI Pharmaceuticals (CASIF) Income from Non-Controlling Interests (2022 - 2023)

CASI Pharmaceuticals' (CASIF) quarterly Income from Non-Controlling Interests came in at -$742000.0 in Q4 2023, up 89.46% YoY from -$391648.2 in Q4 2022, and down 23.67% on a QoQ basis from -$600000.0 in Q3 2023.

CASI Pharmaceuticals (CASIF) Income from Non-Controlling Interests (2022 - 2023) Analysis & Trends

CASI Pharmaceuticals (CASIF) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$742000.0 in Q4 2023.

  • Quarterly Income from Non-Controlling Interests rose 89.46% year-over-year to -$742000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$2.6 million (up 70.23% YoY) and the FY2023 annual result came in at -$2.6 million, up 70.23% from the prior year.
  • Income from Non-Controlling Interests declined to -$742000.0 in Q4 2023, from -$600000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$417000.0 in Q1 2022 to a low of -$7.0 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - 63.60 Mn
10 CASI Pharmaceuticals 2.65 Mn -3.76 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -742,000.00
Sep 30, 2023 -600,000.00
Jun 30, 2023 -593,000.00
Mar 31, 2023 -667,000.00
Dec 31, 2022 -7.04 Mn
Sep 30, 2022 -738,000.00
Jun 30, 2022 -548,000.00
Mar 31, 2022 -417,000.00